Your browser doesn't support javascript.
loading
Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
Narsipur, Nihal; Bulla, Sabrina; Yoo, Connie; Do, Brenda; Tran, Kyle; Gu, Dian; Zhong, Lixian; Wilson, Leslie.
Afiliación
  • Narsipur N; UCSF-Actelion Clinical Research and Medical Communications Fellow, University of California, San Francisco.
  • Bulla S; PharmD Candidates 2021, University of California, San Francisco.
  • Yoo C; PharmD Candidates 2021, University of California, San Francisco.
  • Do B; PharmD Candidates 2021, University of California, San Francisco.
  • Tran K; PharmD Candidates 2021, University of California, San Francisco.
  • Gu D; Institute for Health and Aging, University of California, San Francisco.
  • Zhong L; College of Pharmacy, Texas A&M University.
  • Wilson L; Department of Clinical Pharmacy, University of California, San Francisco.
J Manag Care Spec Pharm ; 27(12): 1691-1702, 2021 Dec.
Article en En | MEDLINE | ID: mdl-34818089
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Análisis Costo-Beneficio / Quimioterapia Combinada / Bortezomib / Lenalidomida / Anticuerpos Monoclonales / Mieloma Múltiple Tipo de estudio: Clinical_trials / Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Límite: Aged / Humans / Middle aged Idioma: En Revista: J Manag Care Spec Pharm Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Análisis Costo-Beneficio / Quimioterapia Combinada / Bortezomib / Lenalidomida / Anticuerpos Monoclonales / Mieloma Múltiple Tipo de estudio: Clinical_trials / Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Límite: Aged / Humans / Middle aged Idioma: En Revista: J Manag Care Spec Pharm Año: 2021 Tipo del documento: Article